{"id":"NCT00038948","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients","officialTitle":"A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-01","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2002-06-07","resultsPosted":"2010-05-14","lastUpdate":"2010-05-14"},"enrollment":830,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Transplantation"],"interventions":[{"type":"DRUG","name":"Sirolimus","otherNames":[]},{"type":"DRUG","name":"tacrolimus","otherNames":[]},{"type":"DRUG","name":"Cyclosporine A","otherNames":[]}],"arms":[{"label":"A","type":"ACTIVE_COMPARATOR"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.","primaryOutcome":{"measure":"Nankivell Glomerular Filtration Rate (GFR)","timeFrame":"52 weeks","effectByArm":[{"arm":"SRL Conversion Strata 20.0-40.0 mL/Min","deltaMin":24.56,"sd":2.42},{"arm":"CNI Continuation Strata 20.0-40.0 mL/Min","deltaMin":27.24,"sd":3.71},{"arm":"SRL Conversion Strata >40.0 mL/Min","deltaMin":59.04,"sd":0.89},{"arm":"CNI Continuation Strata >40.0 mL/Min","deltaMin":57.73,"sd":1.1}],"pValues":[{"comp":"OG000 vs OG001","p":"0.575"},{"comp":"OG002 vs OG003","p":"0.278"}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22143911"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":81,"n":551},"commonTop":["Hyperlipemia","Diarrhea","Hypercholesteremia","Anemia","Infection"]}}